Table 2 Changes in the clinical characteristics of the patients in the TwHF group and valsartan group during the follow-up period

Systolic blood pressure (mmHg)

140.6 ± 15.8

138.4 ± 16.6

135.1 ± 14.3

139.4 ± 16.2

137.9 ± 14.6

138.6 ± 19.7

137.4 ± 14.4

141.9 ± 18.4

0.455

0.943

0.408

Diastolic blood pressure (mmHg)

81.6 ± 11.9

85.0 ± 10.8

79.8 ± 10.3

78.7 ± 10.3

79.1 ± 10.0

77.7 ± 8.8

79.5 ± 8.5

76.5 ± 10.5 †

0.03

0.574

0.253

Urine protein (g/24 h)

4.99 ± 2.25

4.15 ± 1.29

3.23 ± 2.57**#

3.92 ± 1.56

2.83 ± 1.57**#

3.59 ± 1.71

2.99 ± 1.81**#

4.40 ± 2.37

<0.001

0.115

0.001

Serum albumin (g/L)

33.0 ± 5.66

33.0 ± 4.69

33.2 ± 5.35 #

37.7 ± 4.25‡

33.9 ± 5.3

37.4 ± 4.64‡

34.8 ± 5.49

36.3 ± 5.47‡

<0.001

0.368

<0.001

eGFR (ml/min/1.73 m²)

43.07 ± 21.65

47.72 ± 20.34

38.82 ± 19.93

43.59 ± 17.41

40.23 ± 22.24

39.33 ± 16.79‡

38.71 ± 23.66*

36.22 ± 14.96‡

<0.001

0.682

0.009